The Lipid Profile of Human Immunodeficiency Virus-infected Patients Receiving Antiretroviral Therapy at Mpilo Central Hospital Opportunistic Infections Clinic

Main Article Content

N. Maunga
E. Zumbika
K. Mhandire
F. F. Chikuse
G. A. Mavondo


Aims: Long term use of antiretroviral therapy subpopulation living with human immunodeficiency virus is associated with disturbances in blood lipids profiles which are not routinely monitored. More data on such disturbances are needed to persuade the country’s program to institute routine monitoring. This study sought to determine the prevalence and timing of dyslipidaemia in HIV/AIDS naïve people on ART at in Zimbabwe.

Place and Duration of Study: The study was conducted at Mpilo Central Hospital Opportunistic Infections Clinic in Bulawayo, Zimbabwe over a period of three months.

Methods: A cross-sectional study was conducted in HIV-infected persons receiving highly active anti-retroviral treatment at Mpilo Central Hospital Opportunistic Infections Clinic. Lipid assays were determined by Elisa methods. Viral loads and CD4 were measured using the COBAS® TaqMan® and BD FACSCount™ Flow Cytometer, respectively.

Results: A total of 149 consenting participants were enrolled and most (63.2%) were females. The median age of the respondents was 43 years and their median CD4 count was 436 cells/μl after a median duration on ART of 36 months. Viral load was <40 in the majority (68.6%) of the participants. More females (63.1%) were on HAART and were aged >35 (60.4%) years. NNRTI (90.6%) were the more commonly prescribed HAART. The prevalence of dyslipidaemia was 70.2%. Hypercholesterolaemia was observed in 72 (48.3%) patients with 26 being male and 46 being female. High levels of LDL-cholesterol (LDL-c ≥ 3.0 mmol/L) were found in 115 patients with 74 of them being female. Hypertriacylglycerolaemia (TAG ≥ 2.0 mmol/L) was present in 8 cases. The proportion of patients with a low HDL-cholesterol (HDL-c < 1.0 mmol/L) was 15.3% while those with a ratio of TC/HDL-c ≥ 4.1 were 87.5%.

Conclusion: The study demonstrated a high prevalence of dyslipidaemia in HIV-patients receiving HAART. There is a need for the Country’s HIV program to institute laboratory monitoring of blood lipids in patients over one year on HAART.

Dyslipidaemia, high active antiretroviral therapy, human immunodeficiency virus/ acquired immunodeficiency syndrome, hypercholesterolaemia, hypertriacylglycerolaemia.

Article Details

How to Cite
Maunga, N., Zumbika, E., Mhandire, K., Chikuse, F. F., & Mavondo, G. A. (2019). The Lipid Profile of Human Immunodeficiency Virus-infected Patients Receiving Antiretroviral Therapy at Mpilo Central Hospital Opportunistic Infections Clinic. Advances in Research, 20(1), 1-10.
Original Research Article


Grunfeld C, Kotler DP, Hamadeh R. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J. Med. Hyg. 1989;86:27-31.

Husain NEOS, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: Challenges and solutions. HIV/AIDS - Research and Palliative Care. 2014;7:1-10.

Shor-Posner G, Basit A, Lu Y. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J. Med. Hyg. 1993;94:515-519.

Anastos K, Lu D, QS. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J. Acquir Immune Defic Syndr 2007;45:34-42.

Grunfeld C. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J. Med. Hyg. 1989;86:27-31.

Sprinz E, Lazzaretti RK, Kuhmmer R, Ribeiro JP. Dyslipidemia in HIV-infected individuals. Brazilian J. Infect Diseases. 2010;14(6):575-588.


Estrada V, Portilla J. Dyslipidemia related to antiretroviral therapy. AIDS Reviews. 2011;13(1):49–56.

Wlodawer A, Vondrasek J. Terapia anti-aids. Ann Rev Biophysic Biomolecul Struct. 1998;27(249):10-16.

Men’endez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Research. 2013;98(1):93-120.

Palella FJJ, Baker RK, Moorman AC. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J. Acquir Immune Defic Syndr. 2006;43:27-34.

Lohse N, Hansen AB, Pedersen G. Survival of persons with and without HIV infection in Denmark. Ann Intern Med. 2007;146:87-95.

Sackoff JE, Hanna DB, Pfeiffer MR, LV T. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.

Feeney1 ER, Mallon PWG. HIV and HAART-associated dyslipidemia. Open Cardiovascul Med J. 2011;5:49-63.

Berthold HK, Parhofer KG. Ritter MM. Influence of protease inhibitor therapy on lipoprotein metabolism. J. Intern Med. 1999;246:567-575.

Shafran SD, Mashinter LD and Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations HIV Med. 2005;6:421-425.

Lee GA, Seneviratne T, Noor MA. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641-649.

Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: Cholesterol metabolism and beyond. Curr Opin Cell Biol. 2007;19:215-22.

Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 2001;276:37514-37519.

den Boer MA, Berbee JF, Reiss P. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol. 2006;26:124-129.

Mallon PW, Sedwell R, Rogers G. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue Is limited by antiretroviral drug-induced mitochondrial dysfunction. J. Infect Dis. 2008;198:1794-17803.

Nolan D, Hammond E, Martin A. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-1338.

Shikuma CM, Hu N, Milne C. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001;15:1801-1809.

Meininger G, Hadigan C, Laposata M. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism. 2002;51:260-266.

Vigouroux C, Maachi M, Nguyen TH. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.

Moreno-Torres A, Domingo P, Pujol J. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Antivir Ther. 2007;12:195-203.

Bekolo CE, Nguena MB, Ewane L, Bekoule PS, and Kollo B. The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population. BMC Public Health. 2014;14(1):236.

Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, et al. Sex differences in HAART-associated dyslipidaemia. Aids. 2001;15(6):725-734.

Daniyam C, Iroezindu M. Lipid profile of anti retroviral treatment naive HIV infected patients in Jos, Nigeria. Annals of Medical and Health Sciences Research. 2013;3(1):26-30.

Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: A cross-sectional comparative group study. AIDS Research and Therapy. 2012;9(1):31.

Zhou DT, Kodogo V, Chokuona KFV, Gomo E, Oektedalen O, Stray-Pedersen B. Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe. HIV/AIDS (Auckland, NZ). 2015;7:145.

Egana-Gorrono L, Martínez E, Cormand B, Escriba T, Gatell J, Arnedo M. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. AIDS. 2013;27(4):529-538.